The value of pyrazinamide in second phase of short course chemotherapy of pulmonary tuberculosis: an assessment
Rajasekaran, S.; Parmasivam, A.; Sujatha, Kumari and Palanisami, S. (1988) The value of pyrazinamide in second phase of short course chemotherapy of pulmonary tuberculosis: an assessment. Indian Journal of Tuberculosis, 35 (2). pp. 76-79.
Full text available as:
A clinical trial of two short course chemotherapy regimens was undertaken to evaluate the efficacy of pyrazinamide administration in second phase after the one month initial intensive phase. The two regimens were 1 S7H7K7Z7 + 5 H2R2Z2 and 1 S7H,R7Z7 + 5 H2R2. 74.6%. of 150 patients in the former regimen and 73.9% of 153 patients in the latter completed the stipulated treatment Sputum conversion by culture was attained in 98.2% and 92.9% of patients respectively at the end of two months treatment. Relapse rates were 3-92% and 3.12% respectively at the end of one year follow up and the difference was not significant. Thus, pyrazinamide did not contribute any additional benefit in second phase of short course chemotherapy. It is suggested that the initial daily intensive phase of S.C.C., containing pyrazinamide, might be shortened to a period of one month only instead of the conventional two months duration, without compromising its efficacy.
Archive Staff Only: edit this record